Arteritis de células gigantes: actualización diagnóstica y terapéutica by Paloma Muñoz-Reinoso, Ana Domínguez-Mayoral, Francisco J. Toyos-Sáenz de Miera, Laura Castillo-Moreno, Sara Banda-Ramírez, José J. Pérez-Venegas

“…Se han tomado como referencia los protocolos diagnósticos y terapéuticos elaborados por el American College of Rheumatology y la European Alliance of Associations for Rheumatology. Se recomienda la identificación precoz de la enfermedad, y para ello es fundamental la colaboración cercana con otros especialistas. …”
Get full text

Systemic disease activity measured with ESSDAI varies largely over 5 years in a prospective, longitudinal cohort of patients with Sjögren’s disease by Suzanne Arends, Arjan Vissink, Hendrika Bootsma, Liseth de Wolff, Gwenny Verstappen, Alja Stel, Greetje van Zuiden, Jolien van Nimwegen, Frans Kroese

“…Objectives The objectives are to evaluate variation in systemic disease activity (European Alliance of Associations For Rheumatology (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI)) over time at group and individual patient level and to assess associations of ESSDAI low disease activity (LDA) with other outcome measures in a standard-of-care cohort of patients with Sjögren’s disease (SjD).Methods Patients with SjD participating in a prospective longitudinal study (REgistry of Sjögren Syndrome LongiTudinal cohort) fulfilling the 2016 American College of Rheumatology/EULAR classification criteria with ≥2 years of follow-up were included. …”
Get full text

Predicting abatacept retention using machine learning by Rieke Alten, Claire Behar, Pierre Merckaert, Ebenezer Afari, Virginie Vannier-Moreau, Anael Ohayon, Sean E. Connolly, Aurélie Najm, Pierre-Antoine Juge, Gengyuan Liu, Angshu Rai, Yedid Elbez, Karissa Lozenski

“…Retention was defined as treatment for > 365 days or ≤ 365 days in patients who achieved remission or major clinical response (based on European Alliance of Associations for Rheumatology response criteria). The pooled dataset was split into a training/validation cohort for model development and a test cohort for an unbiased evaluation of performance. …”
Get full text

Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort... by Raj Tummala, Richard A Furie, Laurent Arnaud, Eric F Morand, Martin Aringer, Stephanie Chen, Barnabas Desta, Alberta Hoi, Bo Ding, Christine Peschken, Jonatan Hedberg, Tina Grünfeld Eén, Alessandro Sorrentino, Danuta Kielar

“…In subgroup analyses, patients with high IFNGS and high disease activity state (HDAS) at baseline used more immunosuppressants and glucocorticoids compared with those with low IFNGS and non-HDAS at baseline.Conclusions These findings underscore that SLE therapy is still often unable to reach goals as recommended by the European Alliance of Associations for Rheumatology, both with regard to glucocorticoid use and disease activity, suggesting that there is an unmet need for new treatment options for patients with SLE.Trial registration number NCT03189875; 16 June 2017.…”
Get full text

Performance of the modified 2022 ACR/EULAR giant cell arteritis classification criteria without age restriction for discriminating from Takayasu arteritis by Takahiko Sugihara, Masayoshi Harigai, Haruhito A. Uchida, Hajime Yoshifuji, Yasuhiro Maejima, Jun Ishizaki, Yoshiko Watanabe, Hiroaki Dobashi, Yoshinori Komagata, Naoto Tamura, Yoshikazu Nakaoka, Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS)

“…Abstract Objective To evaluate the ability to discriminate giant cell arteritis (GCA) from Takayasu arteritis (TAK) according to the modified 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) GCA classification criteria. …”
Get full text